Tyrosine phosphorylation is important in signaling pathways underlying tumorigenesis. We performed a mutational analysis of the protein tyrosine kinase (PTK) gene family in cutaneous metastatic melanoma. We identified 30 somatic mutations affecting the kinase domains of 19 PTKs and subsequently evaluated the entire coding regions of the genes encoding these 19 PTKs for somatic mutations in 79 melanoma samples. We found ERBB4 mutations in 19% of individuals with melanoma and found mutations in two other kinases (FLT1 and PTK2B) in 10% of individuals with melanomas. We examined seven missense mutations in the most commonly altered PTK gene, ERBB4, and found that they resulted in increased kinase activity and transformation ability. Melanoma cells expressing mutant ERBB4 had reduced cell growth after shRNA-mediated knockdown of ERBB4 or treatment with the ERBB inhibitor lapatinib. These studies could lead to personalized therapeutics specifically targeting the kinases that are mutationally altered in individual melanomas.
Malignant melanoma is the most fatal skin cancer 1, 2 . To develop personalized treatments for advanced disease, it is important to identify genetic alterations leading to melanoma. Protein tyrosine kinases (PTKs) are frequently mutated in cancer (http://www.sanger. ac.uk/genetics/CGP/Census/), and because they are amenable to pharmacological inhibition 3, 4 , further analysis of the PTK gene family could identify new therapeutic strategies. In this study, we used high-throughput gene sequencing to analyze the entire PTK gene family in melanoma, and we identified many previously unreported somatic alterations.
We initially sequenced the coding exons comprising the kinase domains of all 86 members of this gene superfamily in 29 melanomas (Supplementary Table 1 ). A total of 593 exons were extracted from genomic databases and amplified by PCR from cancer-derived genomic DNA samples using specific primers (Supplementary Table 2 ) and directly sequenced with dye-terminator chemistry. We determined whether a mutation was somatic (that is, tumor-specific) by examining the sequence of the gene in genomic DNA from matched normal tissue. From the ~12 Mb of sequence information obtained, we identified 19 genes containing a total of 30 somatic mutations affecting the kinase domains of the proteins. We then analyzed all coding exons of these 19 genes for mutations in a total of 79 melanoma samples using specific primers (Supplementary Table 3) .
We identified 99 nonsynonymous somatic mutations in 19 PTK genes ( Table 1 and Supplementary Fig. 1 ). Only 3 (EPHA6, PDGFRA and PTK2) of the 19 genes have previously been reported to be mutated in melanoma (http://www.sanger.ac.uk/genetics/CGP/Census/). The clinical information associated with the melanoma tumors containing somatic PTK mutations is provided in Supplementary Table 4 .
The observed somatic mutations could either be 'driver' mutations that have a functional role in promoting the neoplastic process or nonfunctional 'passenger' changes. In the 19 genes found to be mutated, we identified 99 nonsynonymous and 17 synonymous mutations, yielding a ratio of nonsynonymous to synonymous changes (N/S ratio) of 5.8:1; this is significantly higher than the N/S ratio of 2.5:1 predicted for nonselected passenger mutations (P < 1 × 10 −5 ) 5 , suggesting that many of these are likely to be 'driver' mutations. The number of C>T mutations was significantly greater than the numbers of other nucleotide substitutions, resulting in a high prevalence of C:G>T:A transitions (P < 1 × 10 −4 ) (Supplementary Fig. 2a) , consistent with mutation signatures previously reported in melanoma 6 .
To evaluate the effect of some of these mutations on kinase function, we focused on ERBB4, the most highly mutated gene in the screen, which harbored 24 somatic mutations (19%). Notably, 5 of the 15 samples containing ERBB4 mutations had more than one somatic mutation in ERBB4, suggesting that such mutations may act synergistically as previously seen for EGFR 7 . The large number of mutations identified in ERBB4 strongly suggests that these mutations may be functionally important in melanoma.
Notably, 7 of the 24 nonsynonymous somatic mutations discovered in ERBB4 affected glutamate residues (P < 5 × 10 −5 , binomial test), all of which resulted in changes to lysine, causing a charge reversal. The underlying reason for this might be the high frequency of C:G>T:A transitions (Supplementary Fig. 2b) Fig. 1 and Supplementary Fig. 3) , with mutations that affect the kinase domain colocalizing with previously described mutations (found in various cancer types at frequencies ranging from 1.1% to 4.7%) 8, 9 and affecting highly conserved residues. These genetic data suggest that mutated ERBB4 is likely to function as an oncogene in melanoma.
ERBB4 (
To prioritize ERBB4 missense mutations for further characterization, we assessed the positions of the affected residues in the protein crystal structure 10, 11 and found that some of the alterations we observed had positioning similar to those caused by mutations reported in the ERBB family members EGFR and ERBB2 in lung cancer, glioblastoma and gastric cancer 12 ( Supplementary Fig. 4 ). On the basis of this analysis, we chose to evaluate the E317K substitution in the extracellular domain, which positioned similarly to the R324L substitution in EGFR; the E542K, R544W and E563K substitutions, which colocalize; the E452K substitution, which was found in two cases; and two substitutions in the kinase domain: E836K, which is found near the N857S substitution in ERBB2, and E872K.
To determine whether the ERBB4 mutants had enhanced kinase activity, we transiently expressed wild-type ERBB4 or the seven mutants (E317K, E452K, E542K, R544W, E563K, E836K and E872K) as well as a kinase-dead version of ERBB4 (K751M) in HEK 293T cells and assessed their catalytic activity using ERBB4 autophosphorylation (both total and at residues Tyr1162 or Tyr1284) as a measure of receptor activation. Compared to wild-type ERBB4, all the missense mutants showed increased phosphorylation of the receptor (Fig. 2a) . No site-specific phosphorylation was seen in cells exogenously expressing the kinase-dead ERBB4. Similar levels of total ERBB4 protein were observed except for kinase-dead ERBB4, whose abundance was higher (Fig. 2a) . To determine whether the increased tyrosine phosphorylation of the ERBB4 mutants correlates with increased kinase activity, we performed a kinase assay using the same set of ERBB4 mutants. The ERBB4 mutants showed markedly higher kinase activity than wild-type ERBB4, although the expression levels of total ERBB4 protein were comparable (Fig. 2b) . As in transfected cells, ERBB4 autophosphorylation was markedly elevated in the melanoma lines harboring ERBB4 mutations compared to melanoma lines harboring endogenous wild-type ERBB4 (Fig. 2c,d) .
ERBB4 is known to activate several downstream signaling pathways, including the ERK and AKT pathways 13 . To evaluate which of these signaling pathways is activated by the ERBB4 mutations, we performed immunoblot analysis of melanoma cell lines harboring endogenous ERBB4 mutations. Phosphorylation of AKT was elevated in cells expressing any of the three evaluated mutant ERBB4 proteins, whereas ERK showed similar activation in cells expressing either wildtype or mutant ERBB4 (Supplementary Fig. 5 ).
To determine whether the ERBB4 variants are transforming, we transiently transfected NIH 3T3 cells with empty vector, wild-type ERBB4, one of the seven constitutively active ERBB4 mutants or oncogenic K-Ras G12V . Ten days after transfection, all the ERBB4 mutants transformed NIH 3T3 cells more efficiently than wild-type ERBB4. Notably, the transformation ability of the ERBB4 mutants was similar to that of oncogenic K-Ras G12V (Fig. 3a,b) . Similarly, expression of mutant ERBB4 significantly increased anchorage-independent growth as assessed by colony formation in soft agar ( Supplementary  Fig. 6a , P < 0.05, t-test). Similar results were seen for several mutants expressed in the human melanoma cell line SK-Mel-2 ( Fig. 3c) , which expresses wild-type ERBB4. Levels of ERBB4 were comparable in all clones ( Supplementary Fig. 6b ).
To assess whether melanoma cells harboring endogenous ERBB4 mutations are dependent on ERBB4 signaling for proliferation, we used short hairpin RNA (shRNA) to stably knock down ERBB4 protein levels in melanoma lines harboring either wild-type (2T and 31T) or mutant ERBB4 (17T, E317K; 63T, E542K/E872K; or 7T, E452K). We confirmed specific targeting of ERBB4 by shRNAs both l e t t e r s immunoprecipitates of melanoma lines harboring wild-type or mutant ERBB4 after serum starvation. Anti-phosphotyrosine 20 (anti-PY20) antibody is specific for phosphorylation at tyrosine residues. Melanoma lines harboring either wild-type or mutant ERBB4 were serum starved, lysed, immunoprecipitated for ERBB4 and then immunoblotted with anti-PY20 or anti-ERBB4. (d) Same as in c, except using a site-specific anti-phosphotyrosine antibody to detect phosphorylation at Tyr1162. S341L  R393W  P409L  E452K  R491K  E542K  R544W  E563K  D609N  P700S  E836K  E872K  G936R  P1033S  R1174Q  S1246N   Receptor L domain GFR domain  331  502  634 718  974  206   I  II  III  IV (Fig. 4a,b) . Three unique shRNA constructs targeting ERBB4 had minimal effect on the proliferation of cells expressing wild-type receptor but substantially reduced the growth of melanoma lines carrying mutant ERBB4 ( Fig. 4c-g ). Thus, mutant ERBB4 is essential for the growth of melanomas harboring these mutations. Evaluation of the effects of ERBB4 knockdown on downstream signaling pathways revealed that downregulation of ERBB4 in cells harboring mutated versions of the gene reduces levels of endogenous phosphorylated AKT but not of phosphorylated ERK. In contrast, inhibition of ERBB4 expression in cells harboring wild-type versions of the gene showed similar levels of AKT and ERK activation (Supplementary Fig. 7 ).
Because shRNA-mediated cell death could result from specific or nonspecific effects, we examined the ability of an exogenous, nontargetable wild-type ERBB4 construct, engineered to be resistant to knockdown by the introduction of three silent mutations in the region of ERBB4 targeted by shRNA no. 6, to rescue the effects of knockdown of endogenous ERBB4. Melanoma cells harboring the E317K mutation stably expressing either control or ERBB4 shRNA no. 6 construct were transduced with the lentiviral non-targetable ERBB4 construct or with the empty vector as control. Similar phosphotyrosine content was seen in both wild-type and non-targetable ERBB4 constructs, demonstrating that the silent mutations in the non-targetable construct do not affect the ability of the receptor to be phosphorylated to wild-type levels (Supplementary Fig. 8a) . Notably, pooled clones of non-targetable reconstituted cells were markedly more resistant to growth inhibition induced by ERBB4 knockdown (no. 6/NT) than were cells infected with the control shRNA (Vect/Vect). 
l e t t e r s
To evaluate mutant ERBB4 as a potential target for specific inhibition of melanoma cell survival, we targeted the ERBB4 pathway with the US Food and Drug Administration-approved pan-ERBB pharmacologic inhibitor lapatinib (GW2016) 14 . Exposure of melanoma cells to lapatinib resulted in a greater reduction in cell proliferation in cells containing endogenous ERBB4 mutations than in cells containing endogenous wild-type ERBB4 (Fig. 5a ). An IC 50 calculation revealed that melanoma cells harboring ERBB4 mutations were 10-to 250-fold more sensitive to lapatinib than cells with wild-type receptor (Fig. 5b) , and treatment with lapatinib inhibited receptor autophosphorylation in a dose-dependent manner (Fig. 5c) . This increased sensitivity to lapatinib was accompanied by specific inhibition of ERBB4 and AKT activation in cells harboring mutant ERBB4 (Fig. 5d,e) . Activation of other downstream elements, such as ERK, was also slightly inhibited by lapatinib ( Supplementary  Fig. 9a,b) . Thus, although signaling by mutant ERBB4 demonstrated selective activation of AKT, lapatinib treatment of cells harboring mutant ERRB4 resulted in uniform inhibition of downstream signaling pathways. Only mutant ERBB4 was inhibited by lapatinib in our melanoma cell lines. No inhibition of its family member ERBB2 was seen (Fig. 5d,e) , and no phosphorylation of EGFR was observed in any of these cells (data not shown). The observed reduced proliferation occurred in cells harboring BRAF, NRAS, ARAF or CRAF mutations in addition to the ERBB4 mutations (Supplementary Tables 5 and 6) .
To elucidate the mechanism of decreased growth of cells expressing mutant ERBB4 after lapatinib treatment, we examined cells for cell cycle perturbations or apoptosis by flow cytometry. Lapatinib markedly increased apoptosis of melanoma cells harboring mutant ERBB4 as compared to lines harboring wild-type ERBB4 (Fig. 5f,g ). Thus, expression of mutant ERBB4 seems to be essential for suppression of proapoptotic signals in melanoma cells harboring these mutations, which is consistent with the selective activation of AKT in ERBB4 mutant cells (Supplementary Fig. 5 ) and with previous results demonstrating an antiapoptotic role for AKT 15 . These results suggest that lapatinib preferentially inhibits the signaling of mutant ERBB4 and that cells with ERBB4 mutations are subject to "oncogene addiction" 16 . Moreover, the enhanced AKT signaling in cells with mutant ERBB4 might provide an additional therapeutic target in these tumors. 
e t t e r s
Previous studies have shown that lapatinib is a much (>10×) more potent inhibitor of EGFR and ERBB2 than of ERBB4 11, [17] [18] [19] . Although lapatinib clearly leads to a loss of ERBB4 phosphorylation, it is not clear that this occurs through direct inhibition of ERBB4 kinase activity. It is possible that the inhibitory effects seen with lapatinib are due to ERBB4 transphosphorylation by EGFR and that lapatinib blocks ERBB4 phosphorylation by directly inhibiting EGFR. Alternatively, it is possible that mutant ERBB4 proteins have higher affinity for binding lapatinib than does wild-type ERBB4. Future work is warranted to investigate the mechanism by which lapatinib effects increased specificity of mutant ERBB4.
Here we describe the identification in melanoma of 99 somatic mutations in 19 PTKs, few of which had previously been linked to melanoma. The high frequency of mutations identified in ERBB4, their colocalization to particular functional domains and the functional studies described above all suggest that these mutations are oncogenic. In contrast to oncogenes with mutational hot spots, such as PIK3CA, BRAF and NRAS, in ERBB4 mutations occur throughout the gene. Our data and the previously reported heterogeneous mutational activation of another oncogene, FLT3, definitively show that not all mutations in oncogenes must be clustered to be functionally important 20 . Changes that affect enzyme activity can result from single or multiple mutations within a gene that increase activity or abrogate negative regulatory domains. Notably, sample 63T harbored two somatic mutations (resulting in the amino acid substitutions E542K and E872K) for which the biochemical effects were assessed separately. Both mutants showed increased receptor autophosphorylation and increased kinase activity. These data demonstrate that both mutations have independent gain-of-function effects, suggesting that they might be synergistic, as has been described previously for mutations affecting EGFR 7, 21 .
Our findings indicate that, if future experiments verify that mutational activation of ERBB4 is essential for tumor growth in vivo, targeting of ERBB4 with small-molecule inhibitors should be considered as a therapeutic approach for the many individuals with melanoma cases carrying these mutations. Broad-spectrum ERBB inhibitors, such as lapatinib and canertinib 14, 22, 23 , already exist. Our results suggest that further development of such inhibitors is warranted and that the clinical utility of this class of compounds in the treatment of melanoma should be explored.
METhods
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. 
oNLINE METhods
Tumor tissues. Tissue and melanoma cell lines used in this study were described previously 24 .
PCR, sequencing and mutational analysis. PCR and sequencing was done as previously described 24 . The kinase domain mutation screen was analyzed using Consed 25 . Variants were called using Polyphred 6.11 (ref. 26) and DIPDetector (N. Hansen, Genome Technology Branch, National Human Genome Research Institute, NIH, unpublished data), an indel detector optimized for improved sensitivity in finding insertions and deletions. Sequence traces of the secondary screen were analyzed using the Mutation Surveyor software package (SoftGenetics).
Construction of wild-type and mutant ERBB4 expression vector. Human ERBB4 (NM_005235) was cloned by PCR as previously described 24 , with primers shown in Supplementary Table 7, using a clone (no. 8327667) purchased from Open Biosystems. The PCR product was cloned into the mammalian expression vector pCDF-MCS2-EF1-Puro (Systems Biosciences) using the XbaI and NotI restriction sites. The E317K, E452K, E542K, R544W, E563K, K751M, E836K, E872K and non-targetable ERBB4 point mutants were made using Phusion PCR for site-directed mutagenesis.
Cell culture and transient expression. Metastatic melanoma tumor lines were maintained as previously described 27 . HEK 293T and NIH 3T3 cells were purchased from the ATCC and maintained in complete DMEM supplemented with 10% FBS, 1× nonessential amino acids, 2 mM L-glutamine and 0.75% sodium bicarbonate. HEK 293T cells were transfected with Lipofectamine 2000 reagent (Invitrogen) at a 6:1 (µl/µg) ratio with DNA using 3-5 µg of plasmid DNA.
Immunoprecipitation and protein blotting. Transfected cells were gently washed three times in PBS and then lysed using 0.5-1.0 ml 1% NP-40 lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1× EDTAfree Complete Protease Inhibitor tablet (Roche), 1 µM sodium orthovanadate, 1 mM sodium fluoride and 0.1% β-mercaptoethanol) per 75-ml flask for 20 min on ice. Lysed cells were scraped and transferred into a 1.5-ml microcentrifuge tube. Extracts were centrifuged for 10 min at 20,000g at 4 °C. Five hundred microliters of supernatant was immunoprecipitated overnight using 20 µl of anti-ERBB4-conjugated agarose beads (Santa Cruz Biotechnology). The immunoprecipitates were washed and subjected to SDS-PAGE and protein blotting as previously described 28 . Primary antibodies used in our analysis were anti-ERBB4 (Santa Cruz Biotechnology), anti-P-ERBB4(Y1162) (Abgent), anti-P-ERBB4(Y1284) (Cell Signaling), anti-PY20 (ZymedInvitrogen), anti-P-ERK1/2(T202/Y204), anti-ERK1/2, anti-P-AKT (S473), anti-AKT (Cell Signaling), anti-P-STAT5A/B(Y694/Y699) (Upstate BiotechMillipore), anti-STAT5 (Cell Signaling) and anti-α-tubulin (Calbiochem-EMD Biosciences).
Pooled stable expression. To make lentivirus, ERBB4 constructs were cotransfected into HEK 293T cells seeded at 1.5 × 10 6 per 75-ml flask with pVSV-G and pFIV-34N helper plasmids (kind gifts from T. Waldman, Georgetown University) using Lipofectamine 2000 as described by the manufacturer. Virus-containing medium was harvested 48-60 h after transfection, filtered, aliquoted and stored at −80 °C.
SK-Mel-2 cells (National Cancer Institute, Division of Cancer Treatment, Developmental Therapeutics Program, Frederick, Maryland, USA) were grown in RPMI-1640 medium (Lonza) and supplemented with 10% FBS (HyClone). SK-Mel-2 and NIH 3T3 cells were seeded at 1.5 × 10 6 cells per 75-ml flask 24 h before infection. Lentivirus for ERBB4 (wild-type and the E317K, E452K, E542K, R544W, E563K, K751M, E836K and E872K point mutants) and empty vector control were used to infect SK-Mel-2 cells or NIH 3T3 cells as previously described 29 . Stable expression of ERBB4 proteins (wild-type and mutants) was determined by SDS-PAGE analysis followed by immunoblotting with anti-ERBB4 and anti-α-tubulin to show equivalent expression among pools. Lentiviral shRNA. Constructs for stable depletion of ERBB4 were obtained from Open Biosystems, and three were confirmed to efficiently knock down ERBB4 at the protein level. Lentiviral stocks were prepared as previously described 24 . Melanoma cell lines (2T, 7T, 17T, 31T and 63T) were infected with shRNA lentiviruses for each condition (vector and scrambled controls and three independent ERBB4-specific shRNAs). Selection and growth were done as described above. Stably infected pooled clones were tested in functional assays.
To rescue shRNA-mediated knockdown of ERBB4 in melanoma cell lines, the non-targetable ERBB4-expressing lentivirus was made as described above and used to infect the melanoma cell line 17T. After infection, cells were given 48-72 h to recover from infection before being tested in functional assays.
Proliferation and growth inhibition assays. To examine growth potential, melanoma cell lines (2T, 7T, 17T, 31T and 63T) stably infected with either vector or scrambled controls or ERBB4-specific shRNAs were seeded into 96-well plates at 2,500 cells per well and incubated for 13-17 d. Samples were analyzed every 48 h by lysing cells in 50 µl 0.2% SDS per well and incubating for 2 h at 37 °C before addition of 150 µl per well of SYBR Green I solution (1:750 (vol/vol) SYBR Green I (Invitrogen-Molecular Probes) in deionized H 2 O).
The effects of tyrosine kinase inhibitors (TKIs) on the proliferation of melanoma cell lines were tested by seeding 96-well plates at 5,000 cells per well in the presence or absence of serum-containing medium and incubating them for 24 h before addition of TKIs. Increasing concentrations of lapatinib (Tykerb, GlaxoSmithKline) were added to each well in four replicates with DMSO as negative control. Plates were analyzed 72 h after addition of TKIs using the SYBR Green I proliferation assay described above.
To further test TKIs on melanoma cell lines, we seeded 96-well plates at 5,000 cells per well and incubated them for 24 h before addition of TKIs (such as lapatinib) at concentrations from 10 nM to 30 µM. Once inhibitors were added, cells were incubated for 72 h at 37 °C. Cells were then analyzed as previously described 18 . Plates were read at 650 nm on a Molecular Devices (Spectra Max) Plate Reader using an absorbance of 650 nm and the data analyzed using SoftMax version 5 and GraphPad Prism version.
Soft agar assay. SK-Mel-2 pooled clones expressing exogenous WT or mutant ERBB4 were plated in duplicate at 1,000 cells per well and NIH 3T3 pooled ERBB4 clones were plated in duplicate at 5,000 cells per well in top plugs consisting of sterile 0.33% Bacto-Agar (BD) and 10% FBS (HyClone) in a 24-well plate. The lower plug contained sterile 0.5% Bacto-Agar and 10% FBS. After 2 weeks, the colonies were photographed and counted.
NIH 3T3 transformation assay. For each plasmid, 150 ng was transfected by the calcium phosphate precipitation method into NIH 3T3 cells cultured in 12-well plates. Twenty-four hours after transfection, 5% of transfected cells were seeded into 25-ml flasks and cultured in normal growth medium for 10 d. The cells were stained with Hema3 (Sigma) and analyzed for the presence of foci.
Analysis of ERBB4 kinase activity. HEK 293T cells were transiently transfected with ERBB4 (wild-type, E317K, E452K, E542K, R544W, E563K, E836K, E872K and kinase-dead K751M) or empty vector and incubated for 18-24 h at 37 °C in medium containing reduced (0.5%) serum before immunoprecipitation. Cells were harvested and ~3 mg of lysate was used in each immunoprecipitation reaction. Immunoprecipitates were performed as described above. Immune complexes were washed three times in lysis buffer and then twice in kinase buffer (20 mM HEPES pH 7.4, 50 mM NaCl, 3 mM MnCl 2 , 20 mM MgCl 2 , 1 mM sodium orthovanadate, 1 mM sodium fluoride and 1× EDTAfree Complete Protease Inhibitor tablet). Immune complexes were then resuspended in 50 µl kinase buffer and 10 µl of the mixture incubated in the presence of [γ-32 P]ATP (3 µCi per reaction) for 15 min at 37 °C. Kinase reactions were stopped by the addition of 2× SDS sample buffer, and phosphorylated samples were resolved on 8% Tris-glycine gels. Gels were stained and de-stained before autoradiography.
Immunoblot quantification analysis. Scanned films from protein blot analysis of SDS-PAGE were analyzed using ImageJ (National Institutes of Health, Bethesda, Maryland, USA). Individual bands were quantified and plots were generated to determine the intensities in each band. The data were then exported to Microsoft Excel and analyzed further for the ratio of phosphoprotein to total protein.
Flow cytometry analysis. Melanoma cells were seeded into 25-ml flasks at densities of 3 × 10 5 cells per flask in normal complete T2 medium and incubated at 37 °C for 24 h before addition of lapatinib. Lapatinib or vehicle was added 72 h at a concentration of 5 µM. Cells were then harvested for FACS analysis by first removing the medium into a new conical tube and then trypsinizing attached cells in 25-ml flasks. Trypsinized cells and those from the medium were combined and washed in ice-cold PBS. Cells were collected by centrifugation at 900g at 4 °C. Ice-cold 70% ethanol was added to cell pellets and allowed to fix overnight at 4 °C followed by washing in ice-cold PBS. DNase-free RNase (Roche) was to cells resuspended in 0.5-1 ml PBS and incubated at 37 °C for 30 min before addition of 50-100 µl propidium iodide (0.5 mg/ml) (Roche). Cellular DNA content was analyzed on Becton Dickinson FACSCalibur using CellQuest software.
X-ray crystal structure assembly. The X-ray crystal structures of the ERBB4 extracellular and kinase domains were used as templates in the program SWISS-MODEL. Location of EGFR and ERBB2 substitutions in the crystal were found by aligning the protein sequences for EGFR, ERBB2, ERBB3 and ERBB4 using ClustalW 30 . Previously known substitutions in EGFR and ERBB2 were matched to the sequence of ERBB4 using the ClustalW alignment.
Statistical analysis. To determine whether the ratio of nonsynonymous to synonymous mutations observed was statistically significant, the exact binomial test was used, with an expected ratio of 2.5:1. All the statistical calculations were performed in the R statistical environment (http://www.r-project.org) 5 . Further statistical analyses were performed using Microsoft Excel to generate P values to determine significance (two-tailed t-test). Inhibition curves (IC 50 ) were analyzed and plotted using GraphPad Prism version 5.
